Corixa (company)
 | This article needs additional citations for verification. (July 2020) |
| This article relies largely or entirely on a single source. (July 2022) |
 | |
| Company type | biotechnology/pharmaceutical |
|---|---|
| Founded | 1994 in Seattle, Washington |
| Defunct | March 31, 2006 |
| Successor | acquired by GlaxoSmithKline |
| Headquarters | Seattle , Washington |
Number of locations | 2 |
| Parent | GlaxoSmithKline (United States)  |
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
In 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
External links[edit]
- "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.
References[edit]
- ^ "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.
47°36′58″N 122°20′03″W / 47.615976°N 122.334242°W
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
Categories:
- Biotechnology companies of the United States
- Defunct companies based in Seattle
- Pharmaceutical companies established in 1994
- Biotechnology companies established in 1994
- Biotechnology companies disestablished in 2006
- 1994 establishments in Washington (state)
- 2005 mergers and acquisitions
- 2006 disestablishments in Washington (state)
- Pharmaceutical companies disestablished in 2006
- GSK plc
- Medical company stubs